Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4496)
All Articles published online
|
Publishing Process of This Article
|
Apr 21, 2013 (publication date) through May 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol 2013; 19(15): 2348-2354 [PMID: 23613628 DOI: 10.3748/wjg.v19.i15.2348] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i15/2348.htm |
| Number | Citing Articles |
| 1 |
Darya B. Rose, Dave Nellesen, Maureen P. Neary, Beilei Cai. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. Journal of Medical Economics 2017; 20(4): 395 doi: 10.1080/13696998.2016.1273228
|
| 2 |
K. Öberg, A. Califano, J.R. Strosberg, S. Ma, U. Pape, L. Bodei, G. Kaltsas, C. Toumpanakis, J.R. Goldenring, A. Frilling, S. Paulson. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Annals of Oncology 2020; 31(2): 202 doi: 10.1016/j.annonc.2019.11.003
|
| 3 |
Michael S. Broder, Eunice Chang, Sheila R. Reddy, Maureen P. Neary. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Pancreas 2017; 46(7): 891 doi: 10.1097/MPA.0000000000000872
|
| 4 |
Matthew H. Kulke, Al B. Benson, Arvind Dasari, Lynn Huynh, Beilei Cai, Todor Totev, Nina Roesner, Mei Sheng Duh, Maureen P. Neary, Victoria E. Maurer, Brandon E. Shih, Cecile G. Dagohoy, Jennifer Chan, Emily K. Bergsland. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. The Oncologist 2019; 24(8): 1056 doi: 10.1634/theoncologist.2018-0519
|
| 5 |
Lisa Bodei, Eric Liu, Scott Paulson, Anthony Gulati, Jon Freudman, William Grosh, Sheldon Kafer, Prasanna C. Wickremesinghe, Ronald R. Salem. Time for a change and to adopt a novel molecular genomic approach in NETs. Nature Reviews Clinical Oncology 2019; 16(4): 269 doi: 10.1038/s41571-019-0185-5
|
| 6 |
Hossein Jadvar. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. American Journal of Roentgenology 2017; 209(2): 277 doi: 10.2214/AJR.17.18264
|
| 7 |
I.M. Modlin, M. Kidd, M. Falconi, P.L. Filosso, A. Frilling, A. Malczewska, C. Toumpanakis, G. Valk, K. Pacak, L. Bodei, K.E. Öberg. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Annals of Oncology 2021; 32(11): 1425 doi: 10.1016/j.annonc.2021.08.1746
|
| 8 |
Tony Cox, Matthew O’Connell, Oscar Leeuwenkamp, Stefan Palimaka, Nicholas Reed. Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset. Current Medical Research and Opinion 2022; 38(8): 1305 doi: 10.1080/03007995.2022.2065146
|
| 9 |
Michael S. Broder, Beilei Cai, Eunice Chang, Tingjian Yan, Al B. Benson. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. Journal of Medical Economics 2018; 21(8): 821 doi: 10.1080/13696998.2018.1474748
|
| 10 |
Louisa G. Gordon, Thomas M. Elliott, Kate Wakelin, Simone Leyden, John Leyden, Michael Michael, Nick Pavlakis, Jan Mumford, Eva Segelov, David K. Wyld. The Economic Impact on Australian Patients with Neuroendocrine Tumours. The Patient - Patient-Centered Outcomes Research 2020; 13(3): 363 doi: 10.1007/s40271-020-00412-z
|
| 11 |
Divya M. Gupta, James Barnes, FeiFei Qin, Kristopher Kapphahn, Kathleen Hornbacker, Douglas W. Blayney, Pamela L. Kunz. Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms. JCO Oncology Practice 2024; 20(2): 203 doi: 10.1200/OP.23.00433
|
| 12 |
Eric Jonasch, Yan Song, Jonathan Freimark, Richard Berman, Ha Nguyen, James Signorovitch, Murali Sundaram. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet Journal of Rare Diseases 2024; 19(1) doi: 10.1186/s13023-024-03060-w
|
| 13 |
Eric Liu, Scott Paulson, Anthony Gulati, Jon Freudman, William Grosh, Sheldon Kafer, Prasanna C. Wickremesinghe, Ronald R. Salem, Lisa Bodei. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. The Oncologist 2019; 24(6): 783 doi: 10.1634/theoncologist.2017-0623
|
| 14 |
Edward M. Wolin, John Leyden, Grace Goldstein, Teodora Kolarova, Ron Hollander, Richard R.P. Warner. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors. Pancreas 2017; 46(5): 639 doi: 10.1097/MPA.0000000000000818
|
| 15 |
Chien-Chia Chuang, Sharvari Bhurke, Shin-Yin Chen, Siham Brulais, Sylvie Gabriel. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. Journal of Medical Economics 2015; 18(2): 126 doi: 10.3111/13696998.2014.975233
|
| 16 |
Arvind Dasari, Emily K. Bergsland, Al B. Benson, Beilei Cai, Lynn Huynh, Todor Totev, Jerome Shea, Mei Sheng Duh, Maureen P. Neary, Cecile G. Dagohoy, Brandon E. Shih, Victoria E. Maurer, Jennifer Chan, Matthew H. Kulke. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. The Oncologist 2019; 24(8): 1066 doi: 10.1634/theoncologist.2018-0520
|
| 17 |
Enrique Grande, Ángel Díaz, Carlos López, Javier Munarriz, Juan-José Reina, Ruth Vera, Beatriz Bernárdez, Javier Aller, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez Fonseca, Marta Trapero-Bertran. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism 2019; 10: 204201881982821 doi: 10.1177/2042018819828217
|
| 18 |
Anna Malczewska, Beata Kos-Kudła, Mark Kidd, Ignat Drozdov, Lisa Bodei, Somer Matar, Kjell Oberg, Irvin M. Modlin. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Advances in Medical Sciences 2020; 65(1): 18 doi: 10.1016/j.advms.2019.10.002
|